DESPITE Sigma's slump in net profit (PD 25 Sep) announced on the ASX yesterday, the companyclaims there were many positive elements to the results.
Commenting on its 2024 half-year results, it still sees positive sales growth across its 300 Amcal-branded pharmacies and 150 Discount Drug Stores, which provides a solid base to achieve the company's medium-term goals.
Group-wide revenue was up 9.4% on a statutory basis to $1.84 billion for the half-year.
The report said high service standards were being regularly demonstrated, with both brands recognised by consumers via Canstar Blue's 2024 Most Satisfied Customer Award (Pharmacies) as the top two ranked marques.
"The focus of the business was to ensure that excellent customer service metrics were backed by a strong in-stock position for all our customers as we prepared for the new Chemist Warehouse Group supply contract.
"Pleasingly, this was achieved with no disruption to our business as evidenced by the Delivery In Full to customers and Despatch On Time metrics averaging above 99%," the report said.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 24
